Alveolar osteitis

RevBio Awarded a $2 Million Follow-On NIH Grant to Reduce Opioid Use and Addiction with TETRANITE®

Retrieved on: 
Wednesday, October 25, 2023
Other Health, Research, Pharmaceutical, Medical Devices, Dental, Clinical Trials, Science, Biotechnology, Medical Supplies, FDA, Other Science, Health, NIDCR, Extraction (chemistry), MMSc, Alveolar osteitis, SBIR, Doctor of Philosophy, United, Multimedia, OUD, Tissue, Phase II, DRS, Tooth, NIH, United States drug overdose death rates and totals over time, Initiative, DMD, Regenerative medicine, Pain management, Addiction, Pain, Patient, Diagnosis, Bangladesh Technical Education Board, Pharmaceutical industry, Dentistry, Medical device

This product is intended to be used to fill extraction sites and mitigate post-operative pain following the removal of wisdom teeth.

Key Points: 
  • This product is intended to be used to fill extraction sites and mitigate post-operative pain following the removal of wisdom teeth.
  • This grant will fund the pre-clinical development of a dental bone graft formulation that will include the release of locally acting non-opioid pain medication.
  • Opioid use disorder (OUD) is a major problem in the US, accounting for 107,622 overdose deaths in 2021.
  • This also expands upon a Phase II SBIR grant ( 1R44DE032564-01 ) which RevBio received from the National Institute of Dental and Cranial Research (NIDCR).

Surgical experts publish updated MRONJ guidance

Retrieved on: 
Tuesday, October 18, 2022
Quality of life, Dentist, Element, Disease, Medicine, Risk, Health care, The Stony Brook School, Infection, American Association of Oral and Maxillofacial Surgeons, UCLA School of Dentistry, Alveolar osteitis, Patient, Osteoporosis, Oral and maxillofacial surgery, Journal of Oral and Maxillofacial Surgery, Necrosis, University, MPH, Oncology, Jaw, Collection, Inflammation, Exhibition, Dental care, Knowledge, Dentistry, Immune system, Commonly used gamma-emitting isotopes, Rheumatology, Oral hygiene, Doctor of Philosophy, Extraction (chemistry), American Association, Oral, Degenerative disease, Association, Committee, Face, Sinusitis, Michigan Medicine, Carlson, Journal, EDM, Gingivitis, Head, Literature, Tobacco, AAOMS, North Memorial Health Hospital, Reconstructive surgery, Cancer, Algorithm, Medical device, MRONJ, DMD, MD, DRS, DDS

ROSEMONT, Ill., Oct. 18, 2022 /PRNewswire/ -- The American Association of Oral and Maxillofacial Surgeons (AAOMS) has issued updated guidance for treating a rare but potentially serious jawbone condition that can impact patients taking antiresorptive medications to treat certain cancer types.

Key Points: 
  • To help patients and healthcare providers navigate this clinical concern, oral and maxillofacial surgery experts analyzed literature and revised guidance to reflect current best practices.
  • Among strategies for reducing the risk of MRONJ: maintaining good oral hygiene, performing high-risk surgical procedures prior to initiating drug therapies, quitting smoking and optimizing diabetes care.
  • Surgical management of MRONJ is increasingly considered a viable method of treatment for all stages of the disease, according to the 2022 guidance.
  • A departure from the three previous position papers, the 2022 recommendations recognize the value of surgical intervention regardless of MRONJ disease stage.